热门资讯> 正文

ALX肿瘤学GAAP每股收益为-0.13美元

2026-08-06 20:14

ALX Oncology press release (ALXO): Q2 GAAP EPS of -$0.13.
Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments as of June 30, 2026, were $153.4 million. The Company believes its cash, cash equivalents and investments are sufficient to fund planned operations through the first half of 2028.

More on ALX Oncology

ALX Oncology: Rebuilding From Critical Setbacks
ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript
ALX Oncology Holdings Inc. 2026 Q1 - Results - Earnings Call Presentation
Alx Oncology outlines interim ASPEN-09 data from ~80 patients by mid-2027 as CD47-high cohort shows 22-month median PFS
Seeking Alpha’s Quant Rating on ALX Oncology

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。